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Mycoplasma  pneumoniae  is  a  non-invasive  pathogen  which  colonizes  the  mucosal 
surface  of the  respiratory  tract  (1-3).  The  resultant  primary  atypical  pneumonia 
occurs  most  frequently  in  children  and  young adults  (4-6),  but  the  incidence  of 
disease  is  probably  underestimated  because  the  symptoms  are  relatively  mild  and 
diagnostic  methods  are  suboptimal  (6,  7).  Infection  with  M.  pneumoniae  is  often 
accompanied by (a)  the appearance of cold agglutinins  in the patient's serum  (8,  9); 
(b) a rise in complement fixation (CF) a titer (8, 10); and (c) the production of antibody 
that  inhibits  metabolic  processes  of the  pathogen  (8,  11,  12).  Still,  the  role  of the 
immune response during M. pneumoniae infection is not understood. Studies performed 
with intranasally infected hamsters demonstrated immunoglobulin-producing cells in 
association with pulmonary infiltrates  (13). Similar experiments cannot be done with 
human tissue because of the infrequency of mortality caused by mycoplasma pneu- 
monia. However, some pertinent  observations have been made with human patients 
and volunteers and with the experimental hamster model. Prior infection with virulent 
M. pneumoniae  provides some protection against  subsequent  disease  in both hamsters 
and humans  (14-18).  It is not known whether this protective effect is due to cellular 
or humoral  immunity or both.  Other reports  suggest  that  humoral  immunity may 
affect disease expression. For example, immunodeficient patients with B cell dysfunc- 
tion are more severely ill with M. pneumoniae infection than normal patients, but show 
no evidence of radiographic pneumonia (19). 
The most commonly used serological test for M. pneumoniae  is a  CF assay that uses 
a  lipid  hapten  extracted  from the organism  as the  target  antigen  (9,  20).  However, 
lipids  are  rarely  good immunogens  unless  complexed  to  protein  (21).  To  evaluate 
whether  specific M.  pneumoniae  proteins  are  immunogenie  during  natural  infection, 
radioimmunoprecipitation  (RIP)  was used to examine infected human and hamster 
sera. This paper reports the identification  of two predominant  proteinaceous  immu- 
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nogens of M. pneumoniae which are  precipitated  by convalescent, but not by acute, 
sera. 
Materials and Methods 
Organisms and Culture Conditions.  Virulent, wild type M. pn~umoniae strains M 129-B 15 (22, 23) 
and M129-B25C (24) were used in this study. Monolayer cultures were grown in 32-oz (~960 
ml) prescription bottles in Hayflick medium (25) at 37°C for 48-72 h, until the phenol red pH 
indicator in the growth medium became orange. The monolayers were washed four times with 
phosphate-buffered saline (PBS)  (pH 7.2) before collection by centrifugation at 9,500 g for 15 
min. For  intrinsic labeling of M. pneumoniae with  [3~S]methionine,  log-phase cultures were 
washed once with PBS and pulsed for 6 h at 37°C with 250/~Ci of L-[sSS]methionine (Amersham 
Corp., Arlington Heights, IL) (1,050-1,400 Ci/mmol sp act) in Hanks' balanced salts solution 
containing 10% dialyzed horse serum. The monolayers were washed once with PBS containing 
1 mM cold methionine, chased for 1.5 h at 37°C in Hayflick medium, and then washed four 
times with PBS containing 1 mM cold methionine before collection as above. Mycoplasmas 
were extrinsically labeled in suspension by a lactoperoxidase-catalyzed radioiodination proce- 
dure (3, 26). Washed M. pneumoniae monolayers or cultures of Mycoplasma orale and Mycoplasma 
salivarium (provided by Dr. J. Tully) were suspended in 1 ml PBS, and 0.5 mCi carrier-free [125I] 
NaI  (Amersham Corp.)  and 50/zg lactoperoxidase  (E.C.  1.11.1.7;  100 IU/mg; Calbiochem- 
Behring Corp., San Diego, CA) were added. The radioiodination reaction was initiated by the 
addition of 25 /zl of 0.001%  hydrogen peroxide,  and  10  min later another 25-/zl aliquot of 
hydrogen peroxide was added. After another 10-min interval, the reaction was terminated by 
the addition of 5 ml phosphate-buffered iodide (PBI; similar to PBS, but with sodium iodide 
substituted for sodium chloride). The iodinated mycoplasmas were pelleted by centrifugation, 
and washed twice with PBI and once with PBS before use. 
Antisera.  Paired  acute  and  convalescent  human  sera  obtained  from  patients  with  M. 
pneumoniae were provided by Dr. C. Helms, University of Iowa, Iowa City, IA. These pairs of 
human sera were selected because they demonstrated a detectable rise in M. pneumoniae CF titer. 
Sequential serum samples obtained from military recruits participating in an M. pneumoniae 
vaccine field trial were provided by Dr. J. Tully and Dr. L. Senterfit. Only those recruits who 
later contracted mycoplasma pneumonia were selected for this evaluation of sequential serum 
response to M. pneumoniae. Control human serum samples collected from patients who did not 
have mycoplasma pneumonia were provided by the clinical pathology department of Medical 
Center  Hospital,  San  Antonio, TX.  Preinfection hamster  sera  were  obtained by  cardiac 
puncture of uninfected Syrian golden hamsters. Some hamsters were then intranasally inocu- 
lated (23, 27) with 108 colony-forming  units (CFU) of M. pneumoniae strain B 15 and bled on day 
26  postinfection to  obtain high-dose-infected anti-M, pneumoniae sera.  For  the  time course 
evaluation of hamster  humoral immune response to  mycoplasma infection, hamsters  were 
intranasally inoculated with ~5 ×  l0  s CFU of wild type, virulent M. pneumoniae strain B25C. 
Hamsters were bled at 1, 2, 4, 8, and 12 wk postinfection. Rabbit anti-M, pneumoniae antiserum 
was  obtained by subcutaneous and  intramuscular injection of  10  x°  CFU of wild  type  M. 
pneumoniae in Freund's complete adjuvant, followed three  weeks  later by a  booster of  10 l° 
mycoplasmas in Freund's incomplete adjuvant. Blood was  drawn 5-14 d  after the booster 
injection. 
Soluble-antigen RIP Assay.  The RIP assay used for the identification of soluble M. pneumoniae 
immunogens  was a modification (28) of the method of Baseman and Hayes (29). Fresh or frozen 
radiolabeled myeoplasma pellets were resuspended in 250/~1 of 10 mM Tris-HC1 (pH 7.8), 0.2% 
(wt/vol) sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulfate (SDS),  10 mM EDTA, 
and 1% (vol/vol) Triton X-100 (TDSET) (30) that contained 100 mM phenylmethylsulfonyl 
fluoride. The suspension was incubated at room temperature for 5 min, 20 #1 of ovalbumin (50 
mg/ml) was added, and the suspension was incubated at 37°C for 15 min. This solution was 
then centrifuged over a cushion of 5% sucrose  in TDSET at  100,000 g for 45 min to remove 
insoluble material. The supernatant was carefully removed and then diluted with TDSET to 
the desired volume. This soluble antigen preparation was divided into 100-/zl aliquots, and 20 
/zl test  antiserum was added. The antigen-antiserum mixtures were incubated at 37°C for  15 
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protein A-bearing Staphylococcus aureus (Staph A) was added to each aliquot, and the suspensions 
were placed on a  rocker platform for 90  min at 4°C.  The Staph A, with adsorbed immune 
complexes, was washed four times with TDSET. The labeled, precipitated antigens were eluted 
by resuspending the Staph A pellet in 30/~1 of 0.1 M Tris-HCl (pH 6.8), 2% (wt/vol) SDS, 20% 
(vol/vol) glycerol, 2% (wt/vol) fl-mercaptoethanol, and 0.02%  (wt/vol) bromophenol blue (SP 
buffer) (31) and boiling the suspension for 3 min. The Staph A was pelleted and the supernatant 
was subjected to SDS-polyacrylamide gel electrophoresis (PAGE). 
Whole-Cell RIP Assay.  Hansen et al. (32) have recently described an RIP procedure which 
permits identification of antibody-accessible proteins on  the cell surface of pathogens.  This 
procedure, which will be referred to as a  whole-cell RIP assay, was used to identify surface 
immunogens  of M. pneumoniae that  are accessible to  antibody in  their native conformation. 
Briefly, [aSS]methionine-labeled M. pneumoniae were suspended in cold PBS, and 125-#1 aliquots 
of this suspension were mixed with 40/d test antisera. The suspensions were placed on a rocker 
platform  for  90  min  at  4°C  to  allow antibody binding  to  accessible mycoplasma surface 
proteins. The mycoplasmas were pelleted in a Microfuge B (Beckman Instruments, Inc., Palo 
Alto, CA) and washed once with PBS to remove unadsorbed antibody. The organisms were 
resuspended in 1.0 ml TDSET, vortexed, and incubated at 37°C for 1 h (with periodic vortexing 
to ensure efficient solubilization). Insoluble material was removed by centrifugation at 45,000 
g for 1 h. The uppermost 0.9 ml of supernatant was carefully transferred to another tube, and 
250/d of washed Staph A was added to each supernatant. The suspensions were placed on a 
rocker platform and incubated for 90 min at 4°C. The Staph A was washed four times with 
TDSET, and adsorbed M. pneumoniae surface immunogens were eluted in 35 p.l SP buffer, as 
described above, before SDS-PAGE. 
Trypsin Treatment of Intact M. pneumoniae.  Intrinsically labeled ([aSS]methionine) M. pneumoniae 
was resuspended in  100/d PBS, and 5.0 #g trypsin (type XI; Sigma Chemical Co., St. Louis, 
MO)  was added. The  suspensions were incubated at  37°C  for  10  min,  and  the enzymatic 
reaction was stopped by the addition of 10 ~g trypsin inhibitor (type II-0; Sigma Chemical 
Co.). After incubation for  10  rain at 0°C,  the trypsin-treated mycoplasmas were used  in  a 
whole-ceU RIP assay. 
SDS-PAGE and Fluorography.  One-dimensional  SDS-PAGE  was  performed  according  to 
Laemmli (33), using a  1.5-mm slab consisting of a 3% stacking and 7.5% separating gel. 14C- 
labeled molecular weight standards  (Bethesda Research  Laboratories, Rockville, MD)  were 
myosin  (200,000),  phosphorylase  b  (92,500),  bovine  serum  albumin  (68,000),  ovalbumin 
(43,000),  and ehymotrypsinogen (25,700).  Upon  completion of electrophoresis, the slab was 
placed in fixative (methanol/acetic acid/H20, 45:10:45) overnight. The gel was then processed 
for fluorography according to the method of Bonner and Laskey (34). 
Results 
Soluble-antigen  RIP of Hamster and Human Sera.  Mycoplasma pneumoniae  proteins that 
are immunogenic  in intranasally inoculated hamsters  and  infected human  patients 
were identified by RIP (Fig. 1). The lane labeled "35S-M. pn." is the one-dimensional 
PAGE  profile  of the  TDSET-soluble  fraction  of total  [aSS]methionine-labeled  M. 
pneumoniae  proteins. The binding of this detergent-soluble fraction to Staph A  in the 
absence  of  antiserum  is  negligible,  as  demonstrated  in  the  lane  designated  "No 
Serum." However, two proteins with apparent molecular weights of 74,000 and 30,000 
are weakly, but consistently, adsorbed to Staph A  in the absence of antiserum.  The 
lanes labeled "Hamster  PB/Inf"  are representative RIP patterns produced by pre- 
bleed  and  postinfection  (day  26,  high-dose  inoculation)  hamster  sera.  Preinfection 
hamster serum precipitates minimal amounts of radiolabeled M. pneumoniae  proteins. 
Precipitation of the 74,000 and 30,000 proteins, which bind weakly to Staph A  in the 
absence of serum, is enhanced in the presence of serum. Postinfection hamster serum 
demonstrates a  response to numerous mycoplasma proteins not recognized by prein- 
fection serum.  Among the predominant  immunogens  that were precipitated postin- LEITH  ET AL.  505 
Fxo.  1.  Soluble-antigen  RIP of intrinsically  labeled M. pnuemoniae with  acute and convalescent 
sera. Mycoplasmas were radiolabeled with  [~S]methionine  and  RIP analysis was performed  as 
described in the text.  From left to right,  the first lane displays the one-dimensional  SDS-PAGE 
profile of the TDSET-soluble  fraction of asS-labeled M. pneumoniae proteins. The second lane shows 
the minimal binding of  TDSET-soluble proteins to Staph A in the absence of acute or convalescent 
sera  (designated "No Serum").  The next  two lanes are representative  RIP profiles produced by 
paired pre-bleed and high-dose infection hamster sera, and the last two lanes are representative RIP 
patterns produced by paired acute and convalescent human sera. Molecular weight markers (K 
10  a) are indicated to the right, and proteins P1 and P2 are indicated on both the right and left. 
fection are proteins with apparent molecular weights of 165,000  and  110,000.  When 
human acute and convalescent sera are assayed by RIP ("Human A/C"), the resultant 
precipitation patterns are remarkably similar to those produced by pre-  and postin- 
fection  hamster  sera.  Examination  of  paired  antisera  by  RIP  revealed  that  the 
majority of infected hamster and human sera precipitated the 165,000 protein during 
convalescence only. However, the  110,000  protein, which was also precipitated by a 
majority of postinfection hamster sera, was precipitated poorly, if at all, by convales- 
cent human  sera. When  15 serum samples obtained from patients who did not have 
M. pneumoniae were tested in the RIP assay, none precipitated the  165,000  or  110,000 
protein  (data  not  shown).  The  165,000  protein  co-migrates  on  SDS-PAGE  with 
protein P1, and the  110,000 protein co-migrates with protein P2, both of which have 
been previously described by us  (3).  Proteins P1  and  P2  have been localized on the 
surface of M. pneumoniae by 125I-labeling and are sensitive to brief trypsin treatment of 
intact  mycoplasmas  (3,  35).  In  addition,  P1  and  P2  bind  in  vitro  to  respiratory 
epithelial cells (35). 
Whole-Cell  RIP.  Immunogens  that  elicit  host  protective  antibody  in  vivo  are 
commonly exposed at the surface of the pathogen and are accessible to antibody. The 
whole-cell RIP assay permitted identification of antibody-accessible immunogens on 
intact  M.  pneumoniae (Fig.  2).  The  first  lane  is  a  total  [35S]methionine-labeled  M. 
pneumoniae protein profile, and the second lane shows the binding of labeled antigens 
to  Staph A  in  the absence of antiserum.  The  next  pair of lanes is representative of 
whole-cell RIP patterns produced by pre-bleed and postinfection (day 26, high-dose 
inoculation) hamster sera, whereas the last two lanes are representative of whole-cell 
precipitation patterns obtained with human acute and convalescent sera. The paired 
sera from hamsters and humans  yield almost identical whole-cell RIP profiles. Note 506  IMMUNOGENIC  PROTEINS  OF M.  PNEUMONIAE 
FIG. 2.  RIP of cell-surface, antibody-accessible 35S-labeled  A~ pneumoniae proteins with acute and 
convalescent sera. The whole-cell RIP assay was performed as described in the text. From left to 
right, the first lane is the SDS-PAGE profile of total [3~S]methionine-labeled  M. pneumoniae proteins. 
The  second lane is the whole-cell RIP  assay with  no  serum  control.  The  remaining  lanes  are 
representative whole-cell RIP profiles of paired pre-bleed and high-dose infection hamster sera and 
paired acute and convalescent human  sera, as indicated. Molecular weight markers (K =  103) and 
proteins P1 and P2 are indicated to the right. 
the decreased precipitation of labeled mycoplasma proteins by hamster preinfection 
and  human  acute  sera  when  the  whole-cell  (rather  than  the  soluble-antigen)  RIP 
assay is used.  Also, hamster and  human  convalescent sera strongly precipitate both 
proteins P1 and P2 in the whole-cell RIP assay, in contrast to the human convalescent 
precipitation pattern detected by the soluble-antigen RIP  (Fig.  1). 
Intrinsically  Labeled  Whole-Cell RIP vs.  Extrinsically  Labeled Soluble-Antigen RIP.  In 
theory,  a  whole-cell  RIP  performed  with  [35S]methionine  intrinsically labeled  M. 
pneumoniae should produce a  precipitation pattern very similar to that derived from a 
soluble-antigen RIP  employing lactoperoxidase-catalyzed, radioiodinated intact  M. 
pneumoniae. Fig. 3 presents such a  comparison. Although the intrinsically and extrins- 
ically  labeled  M.  pneumoniae total  protein  profiles  are  significantly  different,  the 
precipitation of predominant  surface immunogens with either method  ([35S]methio- 
nine whole-cell or x2~I-soluble-antigen RIP)  is nearly identical. These results confirm 
the selective precipitation of surface proteins by the whole-cell RIP assay and indicate 
that  detergent  solubilization  does  not  adversely affect  antibody  recognition  of M. 
pneumoniae antigens. 
Whole-Cell  RIP  of  Trypsinized  M.  pneumoniae.  Brief  trypsin  treatment  of  intact 
mycoplasmas will remove proteins P1  and  P2  from  the surface of the  mycoplasmas 
(3)  and  thus  should abolish precipitation of these proteins by convalescent sera in a 
whole-cell  RIP  assay.  Comparison  of control  and  trypsin-treated  [ZSS]methionine- 
labeled M. pneumoniae total protein profiles revealed that  the band  that  co-migrates 
with  protein P1  is removed upon  trypsinization, whereas the band  that  co-migrates 
with protein P2  is reduced in intensity (Fig. 4).  Convalescent  human  sera no longer 
precipitate either protein  P1  or P2  (or other minor immunogens;  see Figs. 2  and  3) 
when  intact  mycoplasmas are trypsin treated  before use  in  a  whole-cell RIP  assay. 
The  complete  removal  of P2  precipitation  by  antibody  suggests  that  the  residual 
protein at  110,000  remaining after trypsin treatment  is probably another protein of 
the same or similar molecular weight. LEITH  ET  AL.  507 
F~o.  3.  Comparison of precipitation patterns produced by whole-cell RIP of intrinsically labeled 
M. pneumoniae and  soluble-antigen RIP  of extrinsically labeled M.  pneumoniae. From  left  to  right 
in  the  "asS-Whole  Cell"  PAGE  profiles,  lane  1  is  the  SDS-PAGE  profile  of TDSET-soluble, 
[aSS]methionine-labeled mycoplasma proteins.  Lane 2  is the whole-cell  RIP  assay with  no serum 
(NS) control. The next four lanes are representative whole-cell precipitation patterns produced by 
paired acute and convalescent human sera and pre-bleed and high-dose infection hamster sera, as 
indicated. From left to right in the "x25I-Soluble" PAGE profiles, lane 1 is the SDS-PAGE profile of 
total  laSI-labeled M.  pneumoniae proteins.  Radioiodination  of mycoplasmas was  performed  as de- 
scribed in the text. The second lane shows the laSI-labeled, soluble-antigen RIP assay with no serum 
control. The remaining lanes are representative whole-cell precipitation patterns produced by acute 
and  convalescent human sera and  pre-bleed  and  high-dose infection  hamster sera,  as indicated. 
Molecular weight markers (K --  10  a) are indicated to the right. 
Ftn.  4.  Comparison of whole-cell RIP of control and trypsin-treated intact M. pneumoniae. Myco- 
plasmas were  intrinsically labeled  with  [aSS]methionine and  were  incubated briefly with  PBS  or 
trypsin, as described in the text, before use in a whole-cell RIP assay. The control (left) and trypsin- 
treated (right) M. pneumoniae total radiolabeled protein profiles are presented in the first lane of each 
set. Whole-cell RIP of control and trypsin-treated mycoplasmas with a  representative pair of acute 
and  convalescent human sera  produced  the  precipitation  patterns  shown  in  the  accompanying 
lanes, as indicated.  Molecular weight markers (K =  10  a)  and proteins P1  and P2 are indicated to 
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FEG.  5.  Examination of sequential human serological  response to M. pneumoniae infection. Serum 
was collected from patients A, B, and C at the time points indicated, with day  1 representing the 
time of the initial serum sample. The first lane represents the SDS-PAGE profile of TDSET-soluble, 
[zSS]methionine-labeled  M. pneumoniae proteins. The remaining lanes show the precipitation patterns 
produced when the sequential serum samples obtained from patients A, B, and C are subjected to 
soluble-antigen RIP analysis. Proteins P1  and P2 are indicated to the left,  and molecular weight 
markers (K ffi 103) are indicated to the right. 
FIG. 6.  Time  course evaluation of the hamster serological  response to M. pneumoniae infection. 
Hamsters were inoculated intranasally with virulent M. pneumoniae as described in the text. The first 
lane represents the SDS-PAGE profile of TDSET-soluble,  [35S]methionine-labeled M. pneumoniae 
proteins. The remaining lanes depict a soluble-antigen RIP performed with pre-bleed (week 0) and 
postinfection hamster sera drawn from an individual animal at the designated time points. Proteins 
P1 and P2 and molecular weight markers (K ~  103) are indicated. 
Time  Course  Evaluation  of Human  and  Hamster  Serological  Response to  Infection.  To 
further examine the host humoral  response to M. pneumoniae,  sequential serum samples 
obtained  from patients or infected hamsters were examined  by a  soluble-antigen  RIP 
(Figs. 5  and 6). In human  patients, antibody  to P 1 increased and  then decreased with 
time  (Fig.  5).  Note  that  patients  A  and  C  also  demonstrated  a  selective  antibody 
response to protein P2 and a  protein with a  molecular weight of ~  70,000 that followed 
the  same  kinetics  as  the  anti-P1  response.  Hamsters  infected  with  wild  type  M. 
pneumoniae  strain  B25C  similarly  showed  an  increase  in  anti-P1  antibody  as  the LEITH  ET  AL  509 
infection progressed, followed by a decrease with time (Fig. 6). The anti-P2 response 
maximized slightly later than the anti-P1 response, but remained high through 12 wk 
postinfection. 
RIP Using other Mycoplasma Species.  The oropharynx of most humans is colonized 
with  at  least  one  mycoplasma  species  (36).  It  is  possible  that  this  normal  flora 
stimulates a host immune response that is cross-reactive with M. pneumoniae antigens. 
To examine this possibility, M. salivarium and M. orale  were radioiodinated and tested 
in the soluble-antigen RIP assay with rabbit anti-M, pneumoniae antiserum. The total 
protein and RIP patterns were compared with those of M. pneumoniae strain B 15 (Fig. 
7). The iodinated protein profiles of  the three mycoplasma species were very dissimilar. 
Neither oral mycoplasma possessed proteins that co-migrate with protein P1  or P2. 
Anti-M. pneumoniae serum precipitated all iodinated strain B 15 proteins but recognized 
no M. orale or M. salivarium proteins. These data demonstrate that there is little cross- 
reactivity between oral mycoplasmas and M. pneumoniae and further suggest that RIP 
analysis of convalescent sera detects a specific immune response to M. pneumoniae. 
Discussion 
Several M. pneumoniae proteins have been associated with cytadsorption and viru- 
lence (3,  23,  24,  28,  37), which implies that these maeromolecules play an essential 
role in successful parasitism.  The host  immunologic response to mycoplasma pneu- 
monia may be directed against such attachment factors or virulence-specific proteins. 
Although the literature suggests that M. pneumoniae stimulates cellular, humoral, and 
secretory immune responses (13,  18, 38-41), we chose to examine the host humoral 
response to specific mycoplasma proteins. The RIP technique, previously shown to be 
a powerful tool for analyzing the immune response to proteinaceous immunogens of 
pathogens  (29, 30, 32, 42-44), was used to examine acute and convalescent human 
and hamster sera. 
Fio.  7.  Analysis of the specificity of the humoral immune response to M. pneumoniae immunogens. 
Lane A is the total, radioiodinated protein profile obtained from virulent 3,1. pneumoniae. Lane A' is 
the  soluble-antigen  RIP  of radioiodinated  M.  pneumoniae  proteins  by  rabbit  anti-M,  pneumoniae 
antiserum. Lanes B, B' and C, C' are the corresponding profiles produced when radioiodinated M. 
orale (B, B') and radioiodinated M. salivarium  (C, C') are substituted for t25I-labeled M. pneumoniae 
(A, A'). Proteins P1 and P2 and molecular weight markers (K =  103) are indicated. 510  IMMUNOGENIC PROTEINS OF M.  PNEUMONIAE 
Preinfection hamster and acute human sera usually precipitate a small number of 
mycoplasma proteins in the soluble-antigen RIP assay. This precipitation may be due 
to  cross-reactive  antibodies  or  may  result  from  a  nonspecific  binding  of labeled 
mycoplasma proteins  to  Staph  A  that  is  mediated  by nonimmunoglobulin  serum 
components. For example, the 74,000 protein, which is weakly bound to Staph A  in 
the  absence  of antiserum,  shows  enhanced  precipitation  in  the  presence  of many 
serum samples tested. When  the whole-cell RIP is used,  precipitation of the  74,000 
protein (and others) by serum is negligible, which indicates that this protein may be 
cytoplasmic.  Whatever  the  reason  for  background  precipitation  of M.  pneurnoniae 
proteins by preinfection and acute sera, this did not  interfere with identification  of 
immunogens  based  on  increased  precipitation  of specific  mycoplasma proteins  by 
convalescent sera as compared with matched acute sera. 
Proteins P1 and P2 elicit a strong antibody response during convalescence of both 
hamsters and humans infected with M. pneumoniae. The observed anti-P1  response is 
compatible  with  the  immunogenicity  of this  protein  (45).  Excellent  correlation  is 
shown between intrinsically labeled whole-cell RIP and extrinsically labeled soluble- 
antigen RIP, which confirms the surface location of P1  and P2 and the selectivity of 
the whole-cell RIP assay (Fig. 3). The epitopes of proteins P1  and P2 are apparently 
preserved in  the  detergent  system used  for solubilization  of the  mycoplasmas, and 
antigen-antibody complexes are  readily formed and  maintained  in  the  presence of 
this detergent  mixture.  However, trypsin treatment, which  removes P1  and  P2 and 
destroys the attachment capability of M. pneumonme, does abolish precipitation of these 
predominant  immunogens  by  convalescent  sera  in  both  the  soluble-antigen  and 
whole-cell  assays  (Fig.  4  and  data  not  shown).  This  suggests  that  most,  if not  all, 
immunogenic determinants of P1 and P2 are available at the surface of the organism. 
One  potential  shortcoming of the  RIP  technique  is  that  an  immunogen  that  is 
insoluble in the detergent system used would not be detected. Although this possibility 
cannot be ruled out, the similarity of the TDSET-soluble [35S]methionine-labeled M. 
pneumoniae profile  (Fig.  1)  to  the  total  intrinsically  labeled  protein  profile  (Fig.  2) 
indicates that excellent solubilization of the mycoplasmas has occurred. 
The RIP data obtained from sequential serum samples drawn from military recruits 
with mycoplasma pneumonia  (Fig.  5)  and experimentally infected hamsters (Fig.  6) 
indicate that anti-P1  antibody is formed in response to M. pneumoniae infection,  but 
the  level  of  anti-P1  in  the  serum  decreases  with  continuing  convalescence.  The 
hamster anti-P2 response, in contrast, remains strong throughout  12 wk postinfection. 
Also, the hamster anti-P2 precipitate seems to maximize later than the hamster anti- 
P1 precipitate (Fig. 6). In some recruit sera, another protein with a molecular weight 
of ~70,000  is recognized concomitantly with P1  and P2. The observed precipitation 
of additional proteins by certain human sera appears to be the result of a quantitative, 
rather than a  qualitative, phenomenon, since in a whole-cell RIP using recruit sera, 
the precipitation of P2 and the 70,000 protein is greatly enhanced  (data not shown). 
The RIP technique has demonstrated a specific host humoral immune response to 
certain M. pneumoniae proteins. Two predominant  immunogens, proteins P1  and P2, 
stimulate an antibody response only during convalescence of humans and hamsters. 
These proteins do not have correlates in two common oral mycoplasmas, and anti-M. 
pneumoniae antiserum does not precipitate proteins derived from such oral mycoplas- 
mas, which  further  suggests  that  anti-P1  and  anti-P2  are  specifically produced  in LEITH ET AL.  511 
response to M. pneumoniae infection. These data, plus the absence of any false positive 
anti-P1  or anti-P2 responses in a  normal population or in patients hospitalized for 
other illnesses (data not shown), suggest that  proteins P1  and P2 may be useful in 
serodiagnosis of mycoplasma pneumonia. 
Clinical diagnosis of mycoplasma pneumonia is usually based on a fourfold rise in 
the CF titer over a  3 wk period  (9).  The CF test detects antibody directed against 
lipid determinants extracted from M. pneumoniae (9,  10). However, this lipid antigen 
cross-reacts with many plant and animal glycolipids (9, 46). In addition, patients with 
pancreatitis demonstrate high titer antibody against this M. pneumoniae lipid antigen 
(47).  These known potential sources of false positive CF reactions have only empha- 
sized the need for a serodiagnostic test that measures antibody to a specific component 
of M. pneumoniae. The data reported herein suggest  that,  for instance,  an  enzyme- 
linked immunosorbent assay using proteins P 1 and P2 as target antigens may provide 
an improved method for serodiagnosis of mycoplasma pneumonia. 
Proteins P1  and  P2 would appear to be logical components of an M. pneumoniae 
vaccine. However, controversy over the role of serum  antibodies in natural  disease 
remains  unsettled  (14,  16,  18,  40,  48).  Experiments  currently  underway  in  this 
laboratory will evaluate whether anti-P1  and  anti-P2  antisera  have any biological 
effect (bactericidal, opsonic, anti-attachment,  etc.)  on virulent M. pneumoniae. Such 
data should indicate the efficacy of P 1 and P2 as vaccine candidates. It is noteworthy 
that human and hamster sera examined by RIP consistently demonstrate a response 
to  proteins  P1  and  P2,  even  though  these  subjects  were  probably  infected  with 
different strains of M. pneumoniae. This observation further suggests the feasibility of 
using P 1 and P2 as tools in serodiagnosis and vaccine development. 
Summary 
The immune response of experimentally infected hamsters and human patients to 
Mycoplasma  pneumoniae was  examined  by  radioimmunoprecipitation  in  conjunction 
with gel electrophoresis and fluorography. Both intrinsically and extrinsically labeled 
mycoplasma proteins were coincubated with acute and convalescent sera in a radioim- 
munoprecipitation assay. Two M. pneumoniae proteins were selectively precipitated by 
convalescent sera. These predominant immunogens were trypsin-sensitive, antibody- 
accessible surface proteins that co-migrate on polyacrylamide gels with proteins P 1 
and P2, which were previously implicated by us as mediators of cytadsorption. Anti- 
M.  pneumoniae  antiserum  did  not  precipitate  radiolabeled  antigens  derived  from 
Mycoplasma  orale or  Mycoplasma  salivarium.  These  data  indicate  that  M.  pneumoniae 
infection stimulates  a  specific and  highly  targeted  host  antibody  response  to  key 
proteinaceous immunogens. 
We thank Grace Wagner for typing this manuscript. 
Received  for publication 4 October 1982. 
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